ReviewInternational journal of biological sciences2022
The role of DNA mismatch repair in immunotherapy of human cancer.
Review in International journal of biological sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 57 citations in OpenAlex.
- Immunohistochemical Expression of MSH2 and MSH6 Mismatch Repair Proteins and Their Pathological Correlations in Canine Primary Pulmonary Carcinoma.Animals : an open access journal from MDPI · 2026Article
- EMMA-STRAT: a multi-omics based machine learning framework for stratification of endometrial carcinoma molecular subtypes and MSI status.BioData mining · 2026Article
- Leucine-Restricted Diet Attenuates Small Intestinal Tumorigenesis in ApcFood science & nutrition · 2026Article
- Impact of intra-tumoral microbiome on the efficacy of neoadjuvant immunochemotherapy in patients with locally advanced oral squamous cell carcinoma.Journal of translational medicine · 2026Article
- Immunotherapy for pediatric solid tumors: overcoming biological barriers through rational multimodal combinations.Cancer immunology, immunotherapy : CII · 2026Review
- Ancestrally Diverse Autologous Patient-Derived Organoid-Immune Cell Coculture Platform for Addressing Immunotherapeutic Outcome Disparities in High-Grade Endometrial Cancer.Cancer research communications · 2026Article
- Single-Cell and Multiomics Characterization of p21 in Cancer Progression and Therapeutic Sensitivity.Human mutation · 2026Article
- Genetic Variation ofInternational journal of dentistry · 2026Article
- Systematic pan-cancer analysis reveals the prognostic and immunological roles of ectonucleoside triphosphate diphosphohydrolase 6.World journal of clinical oncology · 2025Article
- Comprehensive analysis of zinc finger protein 367 as a potential pan-cancer diagnostic and prognostic biomarker and underlying biological mechanisms.Discover oncology · 2025Article
- Loss of Skeletal Muscle Mass Is Associated With Reduced Cytotoxic T Cell Abundance and Poor Survival in Advanced Lung Cancer.Journal of cachexia, sarcopenia and muscle · 2025Article
- Somatic Mutations in DNA Mismatch Repair Genes, Mutation Rate and Neoantigen Load in Acute Lymphoblastic Leukemia.Pharmaceuticals (Basel, Switzerland) · 2025Article
- CK2α Overexpression in Colorectal Cancer: Evidence for Sex- and Age-Linked Differences.Cancers · 2025Article
- Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.Acta neuropathologica communications · 2025Review
- Targeting DNA Damage Repair to Enhance Antitumor Immunity in Radiotherapy: Mechanisms and Opportunities.International journal of molecular sciences · 2025Review
- The expression of ERAP1 is favorable for the prognosis and immunotherapy in colorectal cancer: a study based on the bioinformatic and immunohistochemical analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- PD-L1 expression and mismatch repair deficiency in locally advanced head and neck squamous cell carcinoma treated with chemoradiotherapy: association with treatment response and survival.Frontiers in immunology · 2025Article
- The role of MCT1 in tumor progression and targeted therapy: a comprehensive review.Frontiers in immunology · 2025Review
- Prostate ductal adenocarcinoma with MLH1 copy number loss, microsatellite instability high and BRCA2 mutation.International cancer conference journal · 2025Article
- DDR1 is identified as an immunotherapy target for microsatellite stable colon cancer by CRISPR screening.NPJ precision oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA mismatch repair (MMR) is an important pathway which helps to maintain genomic stability. Mutations in DNA MMR genes are found to promote cancer initiation and foster tumor progression. Deficiency or inactivation of MMR results in microsatellite instability (MSI) which triggers neoantigen generation and impairs tumor growth. Immunotherapies targeting MMR can increase the burden of neoantigens in tumor cells. While MSI has been regarded as an important predictor of sensitivity and drug resistance for immunotherapy-based strategies. Different approaches targeting genomic instability have been demonstrated to be promising in malignancies derived from different tissues. Underlying MMR deficiency-associated immunogenicity is important for improving the therapeutic efficacy of immunotherapies. In this review we provide an overview of the MMR systems, their role in tumorigenesis, drug resistance, prognostic significance and potential targets for therapeutic treatment in human cancers, especially in hematological malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.